Placental organoids represent an in vitro 3D reconstruction model of the human placenta and of its complex cellular organization to evaluate the pharmacological effect in terms of placentation, gene expression, protein synthesis and placental secretomics.
Placental organoids represent an in vitro 3D reconstruction model of the human placenta and of its complex cellular organization. Placental organoid model can be used in the study of placental pathophysiology. In in particular, it provides a personalized model for sartorial in vitro evaluation of personalized therapeutic efficacy of different pharmacological therapies. In particular, with placental organoid it is possible to evaluate the pharmacological effect in terms of placentation, gene expression, protein synthesis and placental secretomics.
Study Type
OBSERVATIONAL
Enrollment
20
Placenta organoids in vitro treatment with heparin, aspirin, IVIG, filgrastim and metformin
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ostetricia e Patologia Ostetrica
Rome, Lazio, Italy
Development of placental 3D organoid model
Morphological characteristics of placental 3D organoids successfully developed from placentas obtained from full-term physiological pregnancies and pathological conditions (abortion, preeclampsia, preterm delivery). Assessment Parameters: Organoid formation efficiency (%)
Time frame: From the date of caesarean section until the development of placental organoids, assessed up to 36 months.
Characterization of placental 3D organoid model
Assessment of cell viability (live/dead staining)
Time frame: From the date of caesarean section until the development of placental organoids, assessed up to 36 months.
Viability of Placental Organoids
Measurement of cell proliferation rate in normal and pathological placental organoids before and after anticoagulant, anti-inflammatory, and immunomodulatory treatments (heparin, aspirin, metformin, IVIg, filgrastim). Assessment Parameters: Cell viability (live/dead staining)
Time frame: From date of caesarean section until the development of placental organoids, until 36 months
Gene Expression in Placental Organoids
Quantification of tissue-specific gene expression in normal and pathological placental organoids before and after treatments. Assessment Parameters: Differential expression of target genes (qPCR)
Time frame: From date of caesarean section until the development of placental organoids, until 36 months
Secretome Analysis of Placental Organoids
Analysis of extracellular vesicles and soluble factors secreted by placental organoids before and after treatments. Assessment Parameters: Quantification of cytokines by ELISA assay
Time frame: From date of caesarean section until the development of placental organoids, until 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Proliferative Capacity of Placental Organoids
Assessment of percentage of proliferating cells
Time frame: From date of caesarean section until the development of placental organoids, until 36 months
Growth capacity of placental organoids
Assessment of organoid growth rate (diameter increase over time).
Time frame: From date of caesarean section until the development of placental organoids, until 36 months
Protein expression in placental organoids
Assessment of differential expression of proteins by Western blot, immunohistochemistry.
Time frame: From date of caesarean section until the development of placental organoids, until 36 months